Michael Shapiro, DO, FASPC

Michael Shapiro is the inaugural Fred M. Parrish Professor of Cardiology and Molecular Medicine at Wake Forest University where he is on faculty in the Section of Cardiovascular Medicine. After completing a cardiology fellowship, Michael spent two additional years in a clinical and research fellowship focused on advanced cardiovascular imaging at Massachusetts General Hospital/Harvard Medical School. After training, he was on faculty in the Knight Cardiovascular Institute at Oregon Health & Science University. He served as Director of Atherosclerosis Imaging and Associate Director of the Center for Preventive Cardiology. In 2019, he transitioned to Wake Forest University where he serves as the Director of the Center for Prevention of Cardiovascular Disease and the Co-Director of the NIH T32 Cardiovascular Disease Epidemiology and Prevention Research Fellowship Program.

Michael's clinical interests focus on genetic and acquired disorders of cholesterol and triglycerides, atherosclerosis Imaging, genetic predisposition to early myocardial infarction, and cardiovascular risk assessment in apparently healthy individuals. Michael has published extensively in the areas of atherosclerosis imaging, lipid disorders, and preventive cardiology. His current investigative research focuses on PCSK9 physiology and its impact on lipoprotein metabolism. Other areas of research include metabolomics of atherosclerosis, development and validation of automated quantification of breast arterial calcification as a means to refine cardiovascular risk estimation in women, and implementation of machine learning algorithms to identify individuals with familial hypercholesterolemia. He is an established Multiethnic Study of Atherosclerosis and Diabetes Heart Study investigator. He also serves as a principal investigator on numerous clinical trials testing novel lipid modulating therapeutics. Michael is a member of numerous boards and national committees related to preventive cardiology, familial hypercholesterolemia, and lipid disorders.